Abstract:The myeloid-derived suppressor cell (MDSC)-mediated immunosuppressive tumor microenvironment (TME), where tumor hypoxia counts for much, has greatly compromised the outcome of cancer immunotherapy. Here, we demonstrated a strategy for selectively clearing intratumoral MDSCs. Specifically, 2-[2-[2-chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide (IR-780) and metformin (Met) were coloaded into mesoporous silica nanoparticles (MSNs) with CeO2 as the gatekeepers. Controlled release of cargos was achieved upon etching CeO2 with endogenous H2O2. Apart from the drug release, oxygen (O2) was also generated in this process. Importantly, the engagement of Met significantly inhibited mitochondrial respiration, thus working like an O2 economizer. Consequently, the populations and functions of tumor-infiltrated MDSCs were both dramatically reduced through selective alleviation of hypoxia at tumor sites, thus contributing to boosted immune responses. Additionally, the accumulated O2 enhanced IR780-mediated photodynamic therapy, which synergistically strengthened the antitumor efficacy of the platform. To the best of our knowledge, this is the first time to employ an O2-generated and -economized nanoplatform for selectively anergizing MDSC-mediated immunosuppression. We expect that this strategy will shed new light on the clinical cancer immunotherapy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18180?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18180</a>.In vitro release profile of IR780 and Met from CeO2@/Met nanoparticles in plasma. Degradation of H2O2 by CeO2 NPs and the release of O2. Positive area of Ki-67 in tumor tissues after indicated treatments. Positive area of TUNEL in tumor tissues after indicated treatments. Survival curves of B16F10 tumor-bearing mice that received indicated treatments as displayed. Plasma concentration–time curves of CeO2@/Met in mice after intravenous injection. In vivo tissue distribution in B16F10 tumor-bearing mice intravenously injected with indicated treatments at different time points. Quantification of the metastatic nodules on the lung surface of mice under different treatments. Q-PCR analyzed the mRNA level of HIF-α in tumor tissues from B16F10 tumor-bearing mice subjected to indicated treatments. Relative intensity of HIF-1α protein expression by western blotting. Standardized uptake values (SUVs) in solid tumor regions obtained from in vivo PET images taken at 1 h after the injection of 18F-MISO. Relative quantification of MDSCs (CD11b+Gr-1+) in tumor tissues following different treatments. Relative quantification of CTLs (CD3+CD8+) in tumor tissues following different treatments. ELISA assay for IL-10 and TGF-β. Relative intensity of PD-L1 protein expression by western blotting. Histology of the mouse organs collected 21 days after the intravenous injection of CeO2@/Met (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18180/suppl_file/am0c18180_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation

Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Biointerfacing Antagonizing T‐Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy

Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets

Dual-Synergistic Nanomodulator Alleviates Exosomal PD-L1 Expression Enabling Exhausted Cytotoxic T Lymphocytes Rejuvenation for Potentiated Irfa-Treated Hepatocellular Carcinoma Immunotherapy

Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy

Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Abstract 117: Improved PBMC humanized mouse models for immuno-oncology drugs evaluation

Reversing Immune Suppression and Potentiating Photothermal Immunotherapy Via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres

Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy

Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.

Abstract 5737: Enhancing cancer treatment Via a nanostructured chemoimmunotherapy gel facilitating interleukin-2 delivery and immunogenic cell death induction

Bio-responsive Au-miR-183 inhibitor enhances immunotherapy in hepatocellular carcinoma by inducing immunogenic cell death

Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site

Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug